154 related articles for article (PubMed ID: 10436412)
1. Xeloda in the treatment of metastatic breast cancer.
Blum JL
Oncology; 1999 Jul; 57 Suppl 1():16-20. PubMed ID: 10436412
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Blum JL; Jones SE; Buzdar AU; LoRusso PM; Kuter I; Vogel C; Osterwalder B; Burger HU; Brown CS; Griffin T
J Clin Oncol; 1999 Feb; 17(2):485-93. PubMed ID: 10080589
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
4. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
Talbot DC; Moiseyenko V; Van Belle S; O'Reilly SM; Alba Conejo E; Ackland S; Eisenberg P; Melnychuk D; Pienkowski T; Burger HU; Laws S; Osterwalder B
Br J Cancer; 2002 May; 86(9):1367-72. PubMed ID: 11986765
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B
Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247
[TBL] [Abstract][Full Text] [Related]
6. [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Moiseenko VM; O'Reilly SM; Dalbot DC; Van Belle S; Gordon RJ; Griffin T; Osterwalder B
Vopr Onkol; 2000; 46(3):285-9. PubMed ID: 10976273
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience of capecitabine in metastatic breast cancer.
O'Shaughnessy J
Eur J Cancer; 2002 Feb; 38 Suppl 2():10-4. PubMed ID: 11841930
[TBL] [Abstract][Full Text] [Related]
8. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Oshaughnessy JA; Blum J; Moiseyenko V; Jones SE; Miles D; Bell D; Rosso R; Mauriac L; Osterwalder B; Burger HU; Laws S
Ann Oncol; 2001 Sep; 12(9):1247-54. PubMed ID: 11697835
[TBL] [Abstract][Full Text] [Related]
9. [Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer].
Liu X; Song S; Guan Z; Wu S; Duan Y; Yu J; Yang L
Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):71-3. PubMed ID: 11977645
[TBL] [Abstract][Full Text] [Related]
10. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer.
Leonard RC
Br J Cancer; 2001 Jun; 84(11):1437-42. PubMed ID: 11384089
[TBL] [Abstract][Full Text] [Related]
11. Fluoropyrimidines: a critical evaluation.
Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Gradishar WJ; Meza LA; Amin B; Samid D; Hill T; Chen YM; Lower EE; Marcom PK
J Clin Oncol; 2004 Jun; 22(12):2321-7. PubMed ID: 15197193
[TBL] [Abstract][Full Text] [Related]
14. Role of capecitabine (Xeloda) in breast cancer.
Kaklamani VG; Gradishar WJ
Expert Rev Anticancer Ther; 2003 Apr; 3(2):137-44. PubMed ID: 12722873
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Saeki T; Takashima S
Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
17. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
Sternberg CN; Reichardt P; Holland M
Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]